- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/575 - Hormones
Patent holdings for IPC class C07K 14/575
Total number of patents in this class: 1439
10-year publication summary
136
|
115
|
134
|
117
|
127
|
117
|
112
|
105
|
72
|
23
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Novo Nordisk A/S | 2324 |
51 |
Sanofi | 3836 |
29 |
Eli Lilly and Company | 3645 |
24 |
Janssen Pharmaceutica N.V. | 3839 |
23 |
Zealand Pharma A/S | 211 |
20 |
Hanmi Science Co., Ltd. | 145 |
18 |
Protagonist Therapeutics, Inc. | 124 |
18 |
The Regents of the University of California | 18943 |
15 |
Hanmi Pharm. Co., Ltd. | 546 |
14 |
University of Miyazaki | 133 |
14 |
The General Hospital Corporation | 4517 |
13 |
President and Fellows of Harvard College | 5792 |
13 |
Dana-Farber Cancer Institute, Inc. | 2455 |
12 |
Lipoxen Technologies Limited | 65 |
12 |
Centre National de La Recherche Scientifique | 9632 |
11 |
Takeda Pharmaceutical Company Limited | 2961 |
11 |
H. Lundbeck A/S | 1252 |
11 |
Glaxo Group Limited | 4496 |
10 |
Amgen Inc. | 3779 |
10 |
Hybio Pharmaceutical Co., Ltd. | 119 |
10 |
Other owners | 1100 |